MedTrace Logo

Study to Verify the Effectiveness and Safety of Isothymol or Carvacrol Compound Against SARS-CoV-2 in COVID-19 Patients

NCT05445089 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2022-07-08

No results posted yet for this study

Summary

• Check the efficacy, safety and tolerability of the compound Modified isothymol against the SARS-CoV-2 agent in patients COVID-19.

Conditions

  • COVID-19
  • COVID-19 Pneumonia
  • COVID-19 Respiratory Infection
  • COVID-19 Acute Respiratory Distress Syndrome
  • COVID-19 Lower Respiratory Infection

Interventions

DRUG

Carvacrol

Carvativir 6 mg/ml diluted for oral solution.

OTHER

Control group

Placebo

Sponsors & Collaborators

  • Instituto Venezolano de Investigaciones Cientificas

    lead OTHER

Principal Investigators

  • Raul Ojeda, MsC · Biosynthesis Medical

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2020-11-01
Completion
2020-12-15

Countries

  • Venezuela

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05445089 on ClinicalTrials.gov